tiprankstipranks
Bio-Techne (TECH)
NASDAQ:TECH
US Market
TECH
Bio-Techne
RESEARCH TOOLSreports

Bio-Techne (TECH) Stock Forecast & Price Target

531 Followers
See the Price Targets and Ratings of:

TECH Analyst Ratings

Moderate Buy
8Ratings
Moderate Buy
5 Buy
3 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Bio-Techne
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TECH Stock 12 Month Forecast

Average Price Target

$72.00
▲(29.64% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Bio-Techne in the last 3 months. The average price target is $72.00 with a high forecast of $80.00 and a low forecast of $54.00. The average price target represents a 29.64% change from the last price of $55.54.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"47":"$47","64":"$64","81":"$81","55.5":"$55.5","72.5":"$72.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$72.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$54.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[47,55.5,64,72.5,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.48,55.519999999999996,57.559999999999995,59.599999999999994,61.64,63.67999999999999,65.72,67.75999999999999,69.8,71.84,73.88,75.92,77.96,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.48,54.90461538461538,56.32923076923077,57.753846153846155,59.178461538461534,60.60307692307692,62.027692307692305,63.45230769230769,64.87692307692308,66.30153846153846,67.72615384615385,69.15076923076923,70.57538461538462,{"y":72,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.48,53.519999999999996,53.559999999999995,53.599999999999994,53.64,53.68,53.72,53.76,53.8,53.839999999999996,53.88,53.92,53.96,{"y":54,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":57.017,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.342,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.406,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.862,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.483,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.758,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.401,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.674,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.73,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.162,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.82,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 85, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.48,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 105, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$80.00Average Price Target$72.00Lowest Price Target$54.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on TECH
Daniel Markowitz CFA
Evercore ISI
Evercore ISI
$68→$54
Hold
-2.77%
Downside
Assigned
04/06/26
Bio-Techne price target lowered to $54 from $68 at Evercore ISIBio-Techne price target lowered to $54 from $68 at Evercore ISI
TD Cowen Analyst forecast on TECH
Kyle Boucher
TD Cowen
TD Cowen
$80
Buy
44.04%
Upside
Reiterated
03/24/26
Analysts Are Bullish on These Healthcare Stocks: Bio-Techne (TECH), Rhythm Pharmaceuticals (RYTM)
Wells Fargo Analyst forecast on TECH
Brandon Couillard
Wells Fargo
Wells Fargo
$70→$76
Buy
36.84%
Upside
Reiterated
02/06/26
Analysts Offer Insights on Healthcare Companies: Medical Facilities (Other OTC: MFCSF), Bio-Techne (NASDAQ: TECH) and Verastem (NASDAQ: VSTM)
Robert W. Baird Analyst forecast on TECH
Catherine Ramsey Schulte
Robert W. Baird
Robert W. Baird
$61→$70
Hold
26.04%
Upside
Reiterated
02/05/26
Bio-Techne price target raised to $70 from $61 at BairdBio-Techne price target raised to $70 from $61 at Baird
UBS Analyst forecast on TECH
Dan Leonard
UBS
UBS
$70→$79
Buy
42.24%
Upside
Reiterated
02/05/26
Bio-Techne price target raised to $79 from $70 at UBSBio-Techne price target raised to $79 from $70 at UBS
Citi Analyst forecast on TECH
Patrick B Donnelly
Citi
Citi
$70→$80
Buy
44.04%
Upside
Reiterated
02/05/26
Bio-Techne: Near-Term Resilience and Margin Expansion Support Accelerating Growth and Buy Rating Into 2027
Stifel Nicolaus Analyst forecast on TECH
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
$60→$65
Hold
17.03%
Upside
Reiterated
02/05/26
Analysts Offer Insights on Healthcare Companies: Bio-Techne (NASDAQ: TECH) and Aytu BioScience (NASDAQ: AYTU)
William Blair Analyst forecast on TECH
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
02/04/26
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (NASDAQ: LGND), AbbVie (NYSE: ABBV) and Bio-Techne (NASDAQ: TECH)
Deutsche Bank Analyst forecast on TECH
Justin Bowers
Deutsche Bank
Deutsche Bank
$66→$72
Buy
29.64%
Upside
Reiterated
12/12/25
Bio-Techne price target raised to $72 from $66 at Deutsche BankBio-Techne price target raised to $72 from $66 at Deutsche Bank
Argus Research Analyst forecast on TECH
David Toung
Argus Research
Argus Research
$65→$68
Buy
22.43%
Upside
Assigned
11/20/25
Bio-Techne price target raised to $68 from $65 at ArgusBio-Techne price target raised to $68 from $65 at Argus
KeyBanc Analyst forecast on TECH
Paul Knight
KeyBanc
KeyBanc
―
Hold
―
Reiterated
09/12/25
KeyBanc Remains a Hold on Bio-Techne (TECH)
RBC Capital Analyst forecast on TECH
Conor McNamara
RBC Capital
RBC Capital
$61→$73
Buy
31.44%
Upside
Upgraded
09/02/25
Bio-Techne upgraded to Outperform from Sector Perform at RBC CapitalBio-Techne upgraded to Outperform from Sector Perform at RBC Capital
Scotiabank Analyst forecast on TECH
Sung Ji Nam
Scotiabank
Scotiabank
$75
Buy
35.04%
Upside
Reiterated
08/08/25
Bio-Techne (TECH) Gets a Buy from Scotiabank
Benchmark Co. Analyst forecast on TECH
Robert Wasserman
Benchmark Co.
Benchmark Co.
$75
Buy
35.04%
Upside
Reiterated
08/07/25
Leerink Partners Analyst forecast on TECH
Puneet Souda
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
08/05/25
Strategic Divestiture and Focus on Core Strengths Justify Buy Rating for Bio-Techne
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on TECH
Daniel Markowitz CFA
Evercore ISI
Evercore ISI
$68→$54
Hold
-2.77%
Downside
Assigned
04/06/26
Bio-Techne price target lowered to $54 from $68 at Evercore ISIBio-Techne price target lowered to $54 from $68 at Evercore ISI
TD Cowen Analyst forecast on TECH
Kyle Boucher
TD Cowen
TD Cowen
$80
Buy
44.04%
Upside
Reiterated
03/24/26
Analysts Are Bullish on These Healthcare Stocks: Bio-Techne (TECH), Rhythm Pharmaceuticals (RYTM)
Wells Fargo Analyst forecast on TECH
Brandon Couillard
Wells Fargo
Wells Fargo
$70→$76
Buy
36.84%
Upside
Reiterated
02/06/26
Analysts Offer Insights on Healthcare Companies: Medical Facilities (Other OTC: MFCSF), Bio-Techne (NASDAQ: TECH) and Verastem (NASDAQ: VSTM)
Robert W. Baird Analyst forecast on TECH
Catherine Ramsey Schulte
Robert W. Baird
Robert W. Baird
$61→$70
Hold
26.04%
Upside
Reiterated
02/05/26
Bio-Techne price target raised to $70 from $61 at BairdBio-Techne price target raised to $70 from $61 at Baird
UBS Analyst forecast on TECH
Dan Leonard
UBS
UBS
$70→$79
Buy
42.24%
Upside
Reiterated
02/05/26
Bio-Techne price target raised to $79 from $70 at UBSBio-Techne price target raised to $79 from $70 at UBS
Citi Analyst forecast on TECH
Patrick B Donnelly
Citi
Citi
$70→$80
Buy
44.04%
Upside
Reiterated
02/05/26
Bio-Techne: Near-Term Resilience and Margin Expansion Support Accelerating Growth and Buy Rating Into 2027
Stifel Nicolaus Analyst forecast on TECH
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
$60→$65
Hold
17.03%
Upside
Reiterated
02/05/26
Analysts Offer Insights on Healthcare Companies: Bio-Techne (NASDAQ: TECH) and Aytu BioScience (NASDAQ: AYTU)
William Blair Analyst forecast on TECH
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
02/04/26
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (NASDAQ: LGND), AbbVie (NYSE: ABBV) and Bio-Techne (NASDAQ: TECH)
Deutsche Bank Analyst forecast on TECH
Justin Bowers
Deutsche Bank
Deutsche Bank
$66→$72
Buy
29.64%
Upside
Reiterated
12/12/25
Bio-Techne price target raised to $72 from $66 at Deutsche BankBio-Techne price target raised to $72 from $66 at Deutsche Bank
Argus Research Analyst forecast on TECH
David Toung
Argus Research
Argus Research
$65→$68
Buy
22.43%
Upside
Assigned
11/20/25
Bio-Techne price target raised to $68 from $65 at ArgusBio-Techne price target raised to $68 from $65 at Argus
KeyBanc Analyst forecast on TECH
Paul Knight
KeyBanc
KeyBanc
―
Hold
―
Reiterated
09/12/25
KeyBanc Remains a Hold on Bio-Techne (TECH)
RBC Capital Analyst forecast on TECH
Conor McNamara
RBC Capital
RBC Capital
$61→$73
Buy
31.44%
Upside
Upgraded
09/02/25
Bio-Techne upgraded to Outperform from Sector Perform at RBC CapitalBio-Techne upgraded to Outperform from Sector Perform at RBC Capital
Scotiabank Analyst forecast on TECH
Sung Ji Nam
Scotiabank
Scotiabank
$75
Buy
35.04%
Upside
Reiterated
08/08/25
Bio-Techne (TECH) Gets a Buy from Scotiabank
Benchmark Co. Analyst forecast on TECH
Robert Wasserman
Benchmark Co.
Benchmark Co.
$75
Buy
35.04%
Upside
Reiterated
08/07/25
Leerink Partners Analyst forecast on TECH
Puneet Souda
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
08/05/25
Strategic Divestiture and Focus on Core Strengths Justify Buy Rating for Bio-Techne
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bio-Techne

3 Months
xxx
Success Rate
7/9 ratings generated profit
78%
Average Return
+3.81%
reiterated a xxx
 rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +3.81% per trade.
1 Year
Dan LeonardUBS
Success Rate
6/9 ratings generated profit
67%
Average Return
+4.62%
reiterated a buy rating 2 months ago
Copying Dan Leonard's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +4.62% per trade.
2 Years
xxx
Success Rate
6/9 ratings generated profit
67%
Average Return
+4.60%
reiterated a xxx
 rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +4.60% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TECH Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
1
1
Buy
12
8
12
22
24
Hold
23
15
30
85
105
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
35
23
42
108
130
In the current month, TECH has received 25 Buy Ratings, 105 Hold Ratings, and 0 Sell Ratings. TECH average Analyst price target in the past 3 months is 72.00.
Each month's total comprises the sum of three months' worth of ratings.

TECH Financial Forecast

TECH Earnings Forecast

Next quarter’s earnings estimate for TECH is $0.54 with a range of $0.51 to $0.56. The previous quarter’s EPS was $0.46. TECH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TECH has Performed in-line its overall industry.
Next quarter’s earnings estimate for TECH is $0.54 with a range of $0.51 to $0.56. The previous quarter’s EPS was $0.46. TECH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TECH has Performed in-line its overall industry.

TECH Sales Forecast

Next quarter’s sales forecast for TECH is $316.08M with a range of $310.30M to $319.00M. The previous quarter’s sales results were $295.88M. TECH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TECH has Performed in-line its overall industry.
Next quarter’s sales forecast for TECH is $316.08M with a range of $310.30M to $319.00M. The previous quarter’s sales results were $295.88M. TECH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TECH has Performed in-line its overall industry.

TECH Stock Forecast FAQ

What is TECH’s average 12-month price target, according to analysts?
Based on analyst ratings, Bio-Techne’s 12-month average price target is 72.00.
    What is TECH’s upside potential, based on the analysts’ average price target?
    Bio-Techne has 29.64% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TECH a Buy, Sell or Hold?
          Bio-Techne has a consensus rating of Moderate Buy which is based on 5 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Bio-Techne’s price target?
            The average price target for Bio-Techne is 72.00. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $80.00 ,the lowest forecast is $54.00. The average price target represents 29.64% Increase from the current price of $55.54.
              What do analysts say about Bio-Techne?
              Bio-Techne’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of TECH?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.